Details for New Drug Application (NDA): 065114
✉ Email this page to a colleague
NDA 065114 describes PIPERACILLIN, which is a drug marketed by Istituto Bio Ita Spa, Astral, Eugia Pharma, Eugia Pharma Speclts, Fresenius Kabi, Fresenius Kabi Usa, Hospira Inc, Provepharm Sas, Sagent Pharms Inc, Sandoz, Shandong, Steriscience Speclts, and Wockhardt Bio Ag, and is included in twenty-four NDAs. Additional details are available on the PIPERACILLIN profile page.
The generic ingredient in PIPERACILLIN is piperacillin sodium; tazobactam sodium. There are sixteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the piperacillin sodium; tazobactam sodium profile page.
The generic ingredient in PIPERACILLIN is piperacillin sodium; tazobactam sodium. There are sixteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the piperacillin sodium; tazobactam sodium profile page.
Summary for 065114
| Tradename: | PIPERACILLIN |
| Applicant: | Istituto Bio Ita Spa |
| Ingredient: | piperacillin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 065114
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | Nov 14, 2003 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 3GM BASE/VIAL | ||||
| Approval Date: | Nov 14, 2003 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 4GM BASE/VIAL | ||||
| Approval Date: | Nov 14, 2003 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
